España
India
Italia
대한민국
日本
My Account
Benzinga Edge
Benzinga Research
Benzinga Pro
Login
Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Alnylam Pharmaceuticals
ALNY
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$264.99
18.72
7.60%
At close: -
$264.99
0.00
0.00%
After Hours: 4:05 PM EDT
Get Report
Comment
Alnylam Pharmaceuticals (ALNY) Forecast
News
Earnings
Alnylam Pharmaceuticals (ALNY) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Government Trades
Short Interest
Latest news for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock
Alnylam Pharmaceuticals Stock (NASDAQ: ALNY)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Tuesday, January 21, 2025
RBC Capital Reiterates Outperform on Alnylam ...
Benzinga Newsdesk
Thursday, January 16, 2025
(ALNY) - Analyzing Alnylam Pharmaceuticals's Short Interest
Benzinga Insights
Monday, January 13, 2025
$1000 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today
Benzinga Insights
Alnylam Pharmaceuticals shares are trading hi...
Benzinga Newsdesk
HC Wainwright & Co. Reiterates Buy on Alnylam...
Benzinga Newsdesk
What 15 Analyst Ratings Have To Say About Alnylam Pharmaceuticals
Benzinga Insights
Needham Reiterates Buy on Alnylam Pharmaceuti...
Benzinga Newsdesk
Reported Earlier, Alnylam Pharmaceuticals Pre...
Benzinga Newsdesk
Tuesday, January 07, 2025
Bernstein Maintains Outperform on Alnylam Pha...
Benzinga Newsdesk
Friday, January 03, 2025
Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic
Vandana Singh
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 20 Years
Benzinga Insights
Tuesday, December 24, 2024
How Is The Market Feeling About Alnylam Pharmaceuticals?
Benzinga Insights
Monday, December 23, 2024
GIVLAARI Gains Nationwide Reimbursement In Ca...
Benzinga Newsdesk
Monday, December 09, 2024
$100 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth This Much Today
Benzinga Insights
Monday, November 25, 2024
Check Out What Whales Are Doing With ALNY
Benzinga Insights
The FDA Has Alnylam Pharmaceuticals' Suppleme...
Benzinga Newsdesk
Tuesday, November 19, 2024
This Is What Whales Are Betting On Alnylam Pharmaceuticals
Benzinga Insights
Monday, November 18, 2024
Piper Sandler Reiterates Overweight on Alnyla...
Benzinga Newsdesk
HC Wainwright & Co. Reiterates Buy on Alnylam...
Benzinga Newsdesk
Reported Sunday, Alnylam Reported Interim Pha...
Benzinga Newsdesk
Tuesday, November 12, 2024
Alnylam Pharmaceuticals shares are trading lo...
Benzinga Newsdesk
Alnylam Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (24 Ratings)
Benzinga Insights
This Airbnb Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday
Avi Kapoor
Wolfe Research Downgrades Alnylam Pharmaceuti...
Benzinga Newsdesk
Friday, November 08, 2024
Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks
Vandana Singh
Monday, November 04, 2024
Deep Dive Into Alnylam Pharmaceuticals Stock: Analyst Perspectives (24 Ratings)
Benzinga Insights
HC Wainwright & Co. Reiterates Buy on Alnylam...
Benzinga Newsdesk
Friday, November 01, 2024
Raymond James Maintains Outperform on Alnylam...
Benzinga Newsdesk
RBC Capital Reiterates Outperform on Alnylam ...
Benzinga Newsdesk
Scotiabank Maintains Sector Outperform on Aln...
Benzinga Newsdesk
Barclays Maintains Overweight on Alnylam Phar...
Benzinga Newsdesk
Canaccord Genuity Maintains Buy on Alnylam Ph...
Benzinga Newsdesk
Chardan Capital Maintains Buy on Alnylam Phar...
Benzinga Newsdesk
Needham Reiterates Buy on Alnylam Pharmaceuti...
Benzinga Newsdesk
Thursday, October 31, 2024
(ALNY) - Analyzing Alnylam Pharmaceuticals's Short Interest
Benzinga Insights
Alnylam Pharmaceuticals shares are trading lo...
Benzinga Newsdesk
Alnylam Pharmaceuticals Reiterated 2024 Finan...
Benzinga Newsdesk
Alnylam Pharmaceuticals Q3 2024 Adj EPS $(0.5...
Benzinga Newsdesk
Wednesday, October 30, 2024
Alnylam To Showcase Latest Data From TTR Fran...
Benzinga Newsdesk
Wednesday, October 23, 2024
$100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today
Benzinga Insights
Monday, October 21, 2024
TD Cowen Maintains Buy on Alnylam Pharmaceuti...
Benzinga Newsdesk
Friday, October 18, 2024
Avadel Obtains FDA Nod for Label Expansion Of Narcolepsy Drug Lumryz
Zacks
Alnylam Canada Signs LOI From Pan-Canadian Ph...
Benzinga Newsdesk
HC Wainwright & Co. Reiterates Buy on Alnylam...
Benzinga Newsdesk
Thursday, October 17, 2024
Alnylam Stock Up on Cardiomyopathy Drug Regulatory Filing in the EU
Zacks
Wednesday, October 16, 2024
Alnylam Pharmaceuticals shares are trading hi...
Benzinga Newsdesk
MGTX Stock Up on Upbeat Efficacy Data From Parkinson's Disease Study
Zacks
Scotiabank Initiates Coverage On Alnylam Phar...
Benzinga Newsdesk
Alnylam Submits Regulatory Application To Eur...
Benzinga Newsdesk
Monday, October 14, 2024
B of A Securities Maintains Buy on Alnylam Ph...
Benzinga Newsdesk
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch